Evidence map›Paper›PMID 32722884›Full record

ArticleCell proliferation2020

Exosome-transferred long non-coding RNA ASMTL-AS1 contributes to malignant phenotypes in residual hepatocellular carcinoma after insufficient radiofrequency ablation.

Dening Ma, Xinyi Gao, Zhuo Liu, Xingang Lu, Haixing Ju, Ning Zhang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell proliferation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed, 1 pooled it
3.2field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 1 synthesis or guideline pooled it, 62 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Dening MaInstitute of Cancer and Basic Medicine (ICBM), Chinese Academy of Sciences, 1 Banshan East Road, Hangzhou, 310022, China.
Xinyi GaoInstitute of Cancer and Basic Medicine (ICBM), Chinese Academy of Sciences, 1 Banshan East Road, Hangzhou, 310022, China.
Zhuo LiuInstitute of Cancer and Basic Medicine (ICBM), Chinese Academy of Sciences, 1 Banshan East Road, Hangzhou, 310022, China.
Xingang LuInstitute of Cancer and Basic Medicine (ICBM), Chinese Academy of Sciences, 1 Banshan East Road, Hangzhou, 310022, China.
Haixing JuInstitute of Cancer and Basic Medicine (ICBM), Chinese Academy of Sciences, 1 Banshan East Road, Hangzhou, 310022, China.
Ning ZhangDepartment of Hepatic Surgery, Fudan University Shanghai Cancer Center, Cancer Hospital, 270 Dong-An Road, Shanghai, 200032, China.ORCID https://orcid.org/0000-0002-1796-3351
Chinese Academy of Sciences · CNFudan University Shanghai Cancer Center · CN

Funding

National Natural Science Foundation of China 81702371
6 · The paper itself

Abstract

objectivesLong non-coding RNAs (lncRNAs) are emerging RNA regulators in cancer progression, including in hepatocellular carcinoma (HCC). Recently, insufficient radiofrequency ablation (RFA) has been reported to lead to recurrence and metastasis of residual HCC tumours. Herein, we aimed to the role of ASMTL-AS1 in residual HCC after insufficient RFA. MATERIALS AND

methodsIn vitro insufficient RFA model was simulated in Huh7 cells and subsequently named Huh7-H cells. In vitro and in vivo assays were conducted to investigate ASMTL-AS1 function in HCC.

resultsLncRNA ASMTL-AS1 low expressed in normal human liver was found to be highly expressed in HCC tissues and further increased in tumours after insufficient RFA. ASMTL-AS1 expression was related to stage, metastasis and prognosis in HCC. Huh7-H possessed higher ASMTL-AS1 level and more aggressive than Huh7 cells. ASMTL-AS1 contributed to the malignancy of HCC cells both in vitro and in vivo. Mechanistically, ASMTL-AS1 was trans-activated by MYC and promoted NLK expression to activate YAP signalling via sequestering miR-342-3p in HCC. Interestingly, ASMTL-AS1 could be wrapped by exosomes and then convey malignancy through NLK/YAP axis between cells even in residual HCC after insufficient RFA.

conclusionsExosomal ASMTL-AS1 aggravates the malignancy in residual HCC after insufficient RFA via miR-342-3p/NLK/YAP signalling, opening a new road for the treatment of HCC and the prevention of recurrence or metastasis of residual HCC after insufficient RFA.

Indexed as

Gene Expression Regulation, NeoplasticAnimalsCarcinoma, HepatocellularCell Line, TumorDisease ProgressionExosomesHumansLiver NeoplasmsMaleMice, Inbred BALB CMicroRNAsRadiofrequency AblationRNA, Long NoncodingMicroRNAsRNA, Long NoncodingASMTL-AS1exosomesHCCNLKYAP nuclear translocation

Identifiers

PMID32722884
PMCPMC7507479
OpenAlexW3045639313

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.